Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Palbociclib 100mg|DRUG: Palbociclib 125mg|DRUG: Fulvestrant or Tamoxifen or Aromatase Inhibitor
Sponsor: Canadian Cancer Trials Group
Collaborators: Pfizer